Astec Lifesciences Q2 Results FY27: Net Loss Widens to Rs 37.40 Cr, Revenue Rs 72.02 Cr

Astec Lifesciences Ltd (ASTEC) Q2 Results FY27 announced on 26 October 2026, covering the company's financial performance for the July to September quarter. The Consolidated revenue came in at Rs 72.02 Cr and PAT at a loss of Rs 37.40 Cr. The results date places Astec Lifesciences Q2 Results FY27 among the filings reported on NSE and BSE for the September 2026 quarter, and the consolidated results show a wider loss than the year-ago quarter.

This Astec Lifesciences Q2 Results analysis covers the financial highlights, business drivers, outlook and risks of the quarter, using only the numbers Astec Lifesciences reported. Univest has arranged the results analysis in the order investors usually read it, starting with the Financial Highlights table that sets this quarter beside the same quarter last year.

Click Here – Get Free Investment Predictions

Astec Lifesciences Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 72.02 Cr	Rs 73.72 Cr	-2.31% YoY
Operating Profit	Rs -19.79 Cr	Rs -6.69 Cr	-195.81% YoY
Net Profit (PAT)	Rs -37.4 Cr	Rs -24.42 Cr	-53.15% YoY

Source: company filing for Astec Lifesciences Q2 Results FY27, 26 October 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from Astec Lifesciences Q2 Results: What Stands Out

• Revenue: Consolidated revenue declined 2.31% YoY to Rs 72.02 Cr from Rs 73.72 Cr, a small decline on the year-ago quarter.
• Net profit: Net profit was a loss of Rs 37.40 Cr against a loss of Rs 24.42 Cr, a 53.15% YoY change and a wider loss than revenue moved.
• Operating Profit: Operating Profit was a loss of Rs 19.79 Cr against a loss of Rs 6.69 Cr a year earlier, a 195.81% YoY change.
• Margin: Net profit margin narrowed to minus 51.9% from minus 33.1% in the comparison quarter, as reported in Astec Lifesciences Q2 Results FY27.
• Returns: Return on equity stood at minus 25.88% in FY26, and the performance analysis below ties these figures together.

Astec Lifesciences Q2 Results FY27: Performance Analysis

The performance analysis shows Consolidated revenue of Rs 72.02 Cr against Rs 73.72 Cr a year earlier, a 2.31% YoY decline, while net profit was a loss of Rs 37.40 Cr against a loss of Rs 24.42 Cr. The bottom line therefore moved down much faster than revenue in the September 2026 quarter, and Astec Lifesciences Q2 Results FY27 show that gap clearly.

The gap between the two lines shows up in the margin figures. Net profit margin narrowed to minus 51.9% from minus 33.1% in the comparison quarter, which means the loss grew relative to each rupee of revenue. In absolute terms, the loss was wider by Rs 12.98 Cr YoY, and Astec Lifesciences Q2 Results record that change without assigning a cause.

The profit line named Operating Profit followed the same direction, falling to a loss of Rs 19.79 Cr from a loss of Rs 6.69 Cr. Investors reading Astec Lifesciences Q2 Results FY27 may watch whether later quarterly results narrow these losses against the Rs 72.02 Cr revenue level, which is where the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Return on equity – The results analysis points first to return on equity of minus 25.88% in FY26, improved from minus 44.64% in FY25. This is a full-year measure, so it frames the backdrop for the quarter's net loss of Rs 37.40 Cr rather than explaining this quarter alone.

Return on capital employed – Return on capital employed was minus 5.71% in FY26, improved from minus 12.62% in FY25. Within these quarterly results, the FY26 returns sit beside a quarter in which the loss was wider than the Rs 24.42 Cr year-ago figure.

Operating Profit – Operating Profit was a loss of Rs 19.79 Cr against a loss of Rs 6.69 Cr a year earlier. Astec Lifesciences Q2 Results FY27 therefore pair a slightly lower revenue base with a wider operating loss. The data confirms the results but does not establish the specific cause.

FY27 Outlook After Astec Lifesciences Q2 Results

FY27 full-year results will depend on the quarters still to be reported and on disclosed sector conditions. This results analysis therefore treats the Rs 37.40 Cr net loss of the latest quarter as one data point in the year, and it does not extend that figure forward or set any expectation for later quarters.

Astec Lifesciences Q2 Results FY27 give reference levels for the next filings: Consolidated revenue of Rs 72.02 Cr, Operating Profit of minus Rs 19.79 Cr and net profit of minus Rs 37.40 Cr. Readers can compare each coming quarter with these levels and with the year-ago loss of Rs 24.42 Cr, and the Univest Screener lists the same company for follow-up. The risks that deserve attention come next.

Key Risks to Watch After Astec Lifesciences Q2 Results FY27

Revenue Decline

Revenue declined 2.3% year on year to Rs 72.02 Cr in the latest quarter, from Rs 73.72 Cr. A continued gap to the year-ago level would keep the top line under watch in later filings.

Net Loss

The company reported a net loss of Rs 37.40 Cr in the latest quarter, against Rs 24.42 Cr a year earlier. Astec Lifesciences Q2 Results FY27 place this wider loss at the centre of the YoY growth discussion for the quarter.

Narrower Net Profit Margin

Net profit margin narrowed to minus 51.9% from minus 33.1% in the comparison quarter. A lower margin means each rupee of revenue carries a larger loss, which investors can track in the filings that follow.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Astec Lifesciences Q2 Results FY27 record Consolidated revenue of Rs 72.02 Cr and a net loss of Rs 37.40 Cr, with both lines weaker YoY. These quarterly results give readers clear reference levels, and the full figures sit in the Financial Highlights section of this Astec Lifesciences Q2 Results article, also available on the Univest app. Investors should consult a SEBI-registered advisor before acting on any consolidated results.

Frequently Asked Questions on Astec Lifesciences Q2 Results FY27

What are Astec Lifesciences Q2 Results FY27?

Ans. Astec Lifesciences Q2 Results FY27 cover the July to September 2026 quarter, with Consolidated revenue of Rs 72.02 Cr and a net loss of Rs 37.40 Cr, as the Financial Highlights table sets out.

What is the results date for Astec Lifesciences Q2 Results FY27?

Ans. Astec Lifesciences announced Astec Lifesciences Q2 Results FY27 on 26 October 2026. Alongside this results date, the opening paragraphs explain that the filing covers the July to September 2026 quarter on a Consolidated basis.

What revenue was reported in Astec Lifesciences Q2 Results FY27?

Ans. Astec Lifesciences reported Consolidated revenue of Rs 72.02 Cr for the quarter against Rs 73.72 Cr a year earlier, which means revenue declined 2.31% YoY, as the Performance Analysis section explains.

What net profit was reported in Astec Lifesciences Q2 Results FY27?

Ans. Astec Lifesciences reported net profit of minus Rs 37.40 Cr, a loss, against a loss of Rs 24.42 Cr a year earlier, a 53.15% YoY change, and the Key Takeaways section places this beside the revenue move.

How much YoY growth did revenue show in Astec Lifesciences Q2 Results FY27?

Ans. Revenue showed no YoY growth, declining 2.31% from Rs 73.72 Cr to Rs 72.02 Cr, while the Financial Highlights table sets both periods side by side for a direct comparison.

Did net profit rise or fall in Astec Lifesciences Q2 Results?

Ans. Net profit fell in Astec Lifesciences Q2 Results, with the loss widening from Rs 24.42 Cr to Rs 37.40 Cr, a 53.15% YoY change, so the bottom line moved down faster than revenue.

What was the Operating Profit in Astec Lifesciences Q2 Results FY27?

Ans. Operating Profit was a loss of Rs 19.79 Cr in the quarter against a loss of Rs 6.69 Cr a year earlier, a 195.81% YoY change, as the Performance Analysis section details alongside the net loss.

Are Astec Lifesciences Q2 Results consolidated results or standalone results?

Ans. Astec Lifesciences Q2 Results are consolidated results, with revenue of Rs 72.02 Cr and a net loss of Rs 37.40 Cr, so every figure in this article follows that basis, as the introduction states.

What business factors shaped Astec Lifesciences Q2 Results FY27?

Ans. The disclosed factors are return on equity of minus 25.88% and return on capital employed of minus 5.71% in FY26, so these frame Astec Lifesciences Q2 Results FY27 alongside the Operating Profit move covered in Key Business Factors.

What are the key risks after Astec Lifesciences Q2 Results FY27?

Ans. The risks after Astec Lifesciences Q2 Results FY27 are the 2.31% YoY revenue decline, the net loss of Rs 37.40 Cr and a net profit margin that narrowed to minus 51.9% from minus 33.1%, as the Key Risks section details.

What is the outlook after Astec Lifesciences Q2 Results?

Ans. FY27 full-year results will depend on the quarters still to be reported, so the outlook after Astec Lifesciences Q2 Results stays tied to later filings and disclosed sector conditions, as the Outlook section explains.

Where can I find the complete Astec Lifesciences Q2 Results FY27 data?

Ans. The complete Astec Lifesciences Q2 Results FY27 data sits in the Financial Highlights table of this article, and readers can review the same figures on the Univest Screener, as the Conclusion also points out.